Clinical trials
Multiple Myeloma and Plasma Cell Neoplasm clinical trials
Below are recruiting multiple myeloma and plasma cell neoplasm clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07529782RecruitingPhase 1
Safety and Efficacy of HDP-101 in Relapsed or Refractory Multiple Myeloma
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT07336472RecruitingPhase 1/Phase 2
IBI3003 for relapsed or refractory multiple myeloma
This trial tests a new drug called IBI3003 for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if IBI3003 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT07319897RecruitingPhase 2/Phase 3
BCMA PET scan for multiple myeloma imaging
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
Beijing, Beijing MunicipalityAges 18–80 - NCT07085559RecruitingEarly Phase 1
Metabolically armed BCMA CAR-T for relapsed plasma cell cancer
This trial tests a new type of CAR-T cell therapy (Meta10-BCMA) that is "metabolically armed" to better fight cancer cells. It's for people with plasma cell cancers that have come back or not responded to multiple prior treatments, and whose cancer cells carry the BCMA protein.
Hefei, AnhuiAges 19–75 - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT06768489RecruitingPhase 1
Combination therapy for multiple myeloma and related conditions
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06760052Recruiting
Plasma Cell Disorder Long-Term Registry Study
This study creates a long-term database of patients with plasma cell disorders (such as multiple myeloma) to improve future care. You would be helping doctors learn more about these conditions by sharing your records over time.
Shanghai, Shanghai MunicipalityAges 19–99 - NCT06717113RecruitingEarly Phase 1
A new imaging test for multiple myeloma
This trial tests a special imaging dye that targets a protein called BCMA on multiple myeloma cells. It may help doctors see and diagnose the disease more clearly during bone marrow or tissue biopsies.
Beijing, Beijing MunicipalityAges 18–80 - NCT03858205Recruiting
Low-dose radiation to relieve pain from bone tumors
This trial studies whether low-dose radiation can reduce pain from a specific bone lesion caused by multiple myeloma. It may help people whose main problem is painful bone metastasis, with targeted treatment to the painful spot.
Duarte, CaliforniaAges 18 years+ - NCT07519187RecruitingEarly Phase 1
CAR-T Cell Therapy for Hard-to-Treat Blood Cancers
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack cancer cells in patients with multiple myeloma, plasmacytoma, plasma cell leukemia, or light chain amyloidosis that have not responded well to previous treatments. The goal is to see if this approach can help patients whose cancers have become resistant to standard medicines.
Chengdu, ChengduAges 18–75 - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT04483206RecruitingPhase 1
Personalized stem cell transplant for multiple myeloma
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Atlanta, GeorgiaAges 18 years+ - NCT07454382RecruitingPhase 2
Study of elranatamab and cyclophosphamide for multiple myeloma
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
Basking Ridge, New JerseyAges 18 years+ - NCT06271252RecruitingPhase 1
Study of OriCAR-017 for relapsed or refractory multiple myeloma
This trial tests a new type of CAR-T cell therapy called OriCAR-017 for people with multiple myeloma that has come back or not responded to treatment. It is for patients who have already tried several treatments, including ones that target BCMA, and their last treatment stopped working.
Atlanta, GeorgiaAges 18–75 - NCT01137825Recruiting
Older patient cancer registry for a health check
This study is a registry that collects information from older adults who may be dealing with cancer. It includes a short health and function check to help doctors understand needs and guide care, even for people who turn out not to have cancer.
Boone, North CarolinaAges 65 years+ - NCT06083207RecruitingPhase 1/Phase 2
IBI3003 for multiple myeloma that has returned or not responded
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
Wollongong, New South WalesAges 18 years+ - NCT05996367Recruiting
Single radiation dose for painful myeloma bone lesions
This trial is testing whether a single dose of radiation can effectively relieve bone pain caused by multiple myeloma. It is designed for people who have a painful bone lesion and are stable on or off treatment.
São Paulo, São PauloAges 18–85 - NCT05651932RecruitingPhase 1
Test of an MMSET inhibitor for relapsed multiple myeloma
This Phase 1 trial tests a new drug that targets MMSET in people whose multiple myeloma has returned or not responded to prior treatment. It aims to find a safe dose and see whether it can shrink myeloma in this setting.
San Francisco, CaliforniaAges 18 years+ - NCT05556928Recruiting
Cancer and aging study for adults with blood cancers
This study builds a registry to learn how aging and “resilience” relate to outcomes in people with blood cancers. You may be asked to complete questionnaires during UAB visits, which can help researchers better understand needs in older adults.
Birmingham, AlabamaAges 50 years+ - NCT05573802RecruitingPhase 1/Phase 2
Belantamab and other medicines for new multiple myeloma
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
AthensAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Anchorage, AlaskaAges 40–75 - NCT04776330RecruitingPhase 1/Phase 2
BCMA-targeted CAR-T for relapsed or refractory multiple myeloma
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Kunming, YunnanAges 18–75 - NCT04271644RecruitingPhase 1/Phase 2
CAR-T treatment targeting BCMA for hard-to-treat myeloma
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Kunming, YunnanAges 18–75
Hear when a new Multiple Myeloma and Plasma Cell Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma and plasma cell neoplasm?
- Yes. Clin2 currently lists 32 recruiting multiple myeloma and plasma cell neoplasm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma and plasma cell neoplasm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma and plasma cell neoplasm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.